ClinicalTrials.gg
Not yet recruitingNCT05934812Updated Jun 24, 2024

Intranasal Oxytocin in Youth With Autism

A Phase 2 interventional study of Oxytocin nasal spray and Placebo in Autism Spectrum Disorder, sponsored by Oslo University Hospital. Not yet recruiting at 1 site in Norway. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Oslo University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
12 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing oxytocin in Autism Spectrum Disorder — 2 open to participants now, 2 under way, none of them phase 3. Oxytocin · Autism Spectrum Disorder.

Planned enrollment
Largest of 23
128 · median 30
Started
2024
the only one that year
Phase 2
13 of 23
2 open now
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Oslo University Hospital

Among the 23 studies testing oxytocin in Autism Spectrum Disorder, this one has the largest planned enrollment, is the only one that started in 2024, is one of 13 in phase 2, and was the 23rd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

2 of the 23 studies testing oxytocin in Autism Spectrum Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 12 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing oxytocin in Autism Spectrum Disorder, or all of them as a file.
02

Study summary

Growing evidence demonstrates the critical contribution of the neuropeptide oxytocin in the development and maintenance of autism, due to its role in social behaviour and learning processes. While some preliminary findings in oxytocin administration trials have been promising, a complete understanding of the effects of long-term oxytocin administration in autism remains elusive, as participant numbers in oxytocin administration studies in autism have been small, most studies exclusively recruit males, and reproducibility has been inconsistent.

To address this critical knowledge gap, this project will include a double-blind, placebo-controlled, randomized controlled crossover trial of a four-week intranasal oxytocin treatment (24 international units, twice-daily) in 128 male and female youth with ASD aged 12-20, with social and repetitive behaviors as primary outcome measures. The investigators predict that intranasal oxytocin treatments will increase performance on social behavior measures and reduce repetitive behaviors using caregiver-reported measures.

Along with the investigation of oxytocin's long-term effects, the investigators will also assess the impact of oxytocin administration on computer-based laboratory tasks that can precisely measure how participants process social cues and disengage with repetitive behaviours. In addition, an electrocardiogram will be collected to evaluate the impact of oxytocin administration on parasympathetic nervous system activity.

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants between the ages of 12 and 20, both inclusive, with a confirmed diagnosis of autism spectrum disorder (ASD) diagnosis as per the ADOS/ADI.
  2. Participants must be in good general physical health, as determined by the investigator.
  3. Participant's pre-study physical examination and vital signs must not show any abnormalities as determined by the investigator.
  4. Participants and caregivers must be able to communicate well with the investigator, to understand and comply with the requirements of the study, and to understand the oral and written study information

Exclusion criteria

Exclusion Criteria:

  1. Previous nasal disease, surgery, and dependence on inhaled drugs.
  2. Current significant nasal congestion due to common colds.
  3. history of significant hepatic, renal, endocrine, cardiac, nervous, pulmonary, haematological or metabolic disorder.
  4. Systemic illness requiring treatment within 2 weeks prior to Study Day 1.
  5. Full scale IQ \< 70 (due to the prerequisite ability to complete self-report measures).
  6. Known allergic reactions or to any component of the study medication in the nasal spray, such as propyl parahydroxybenzoate (E216), methyl parahydroxybenzoate (E218) and chlorobutanol hemihydrate.
  7. Known allergic reactions or hypersensitivity/intolerance to latex
  8. Currently breastfeeding
  9. Pregnancy (self-reported or assessed by pregnancy test prior to the first administration at Experimental session 1 and 2 for all menstruating females)
  10. Participation in any (other) clinical trial with an medicinal product or medical device within 3 months prior to randomisation.
  11. New concomitant medications or formal cognitive/behavioral therapies. If a participant has been taking any medications or receiving formal cognitive/behavioral therapies for at least 4 weeks, then this is not considered a new therapy.
  12. Other unspecified reasons that, in the opinion of the investigator or the sponsor make the participants unsuitable for enrolment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Oxytocin

    24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily

    Drug: Oxytocin nasal spray

  • Placebo comparator
    Placebo

    Placebo delivered with a pump-actuated nasal spray device, administered twice-daily

    Drug: Placebo

Interventions

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily

  • DrugPlacebo

    Placebo liquid nasal spray administered twice-daily

06

What researchers measure

Primary outcomes

  1. Social behavior

    Assessed by the total score of the Social Responsiveness Scale-Second Edition (SRS-2), as completed by caregivers of the participants. Lower scores represent better outcomes.

    Time frame: Four weeks

  2. Repetitive behaviour

    Assessed with the Repetitive Behavior Scale-Revised (RBS-R), as completed by caregivers of the participants. Lower scores represent better outcomes.

    Time frame: Four weeks

Secondary outcomes

  1. Behavioral inflexibility

    Assessed by the Behavioral inflexibility scale (BIS), completed by caregivers of the participants. Lower scores represent better outcomes.

    Time frame: Four weeks

  2. Social cognition

    Assessed by a computerized Emotional body language task completed by the participants. Higher accuracy scores represent better outcomes.

    Time frame: Four weeks

  3. Repetitive cognition

    Assessed by a computerised probabilistic reversal learning task completed by participants. More regressive errors represent worse outcomes (i.e., after initially choosing the new correct response, participants regress back to choosing the previously rewarded response)

    Time frame: Four weeks

  4. Vagally-mediated heart rate variability

    Calculated using electrocardiogram (RMSSD and High Frequency HRV)

    Time frame: Four weeks

Other outcomes

  1. Participation in social activities

    As measured by the Participation and Environment measure-Child and Youth scale. Higher scores on the "participation frequency", "level of involvement", and "Percent total environmental supportiveness" subscores represent better outcomes, and lower scores on the "Percent never participates" and "Percent that parents desired change" represent better outcomes

    Time frame: Four weeks

  2. Caregiver quality of life

    As measured by the Care-related Quality of Life instrument (CarerQol). Higher scores represent better outcomes

    Time frame: Four weeks

  3. Executive function

    As measured by the Behavior Rating Inventory of Executive Functions. Lower scores represent better outcomes

    Time frame: Four weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — This needs to confirmed with local data protection authorities

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Nov 2025, 13 months later.

Of 68 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 13 months is below that.

Counting every sponsor, half of 83 studies reached it within 36 months; a quarter within 23 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2023
First posted
Jul 7, 2023
StartEst.
Sep 18, 2024
Primary completionEst.
Nov 4, 2025
CompletionEst.
Nov 4, 2025
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05934812
Collaborators
University of Oslo
Responsible party
Ole A. Andreassen (Professor, Oslo University Hospital) — Principal investigator
First posted
Jul 7, 2023
Start date
Sep 18, 2024 (estimated)
Primary completion
Nov 4, 2025 (estimated)
Completion
Nov 4, 2025 (estimated)
Last update
Jun 24, 2024

Study contacts

Daniel S Quintana, PhD
Contact
daniel.quintana@psykologi.uio.no
+47 22 84 50 00
Ole A Andreassen, PhD, MD
principal investigator · University of Oslo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion